American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report-Reference-Cited by-同舟云学术

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report

Published:2011-07 Issue:1 Volume:128 Page:210-212
ISSN:0091-6749
Container-title:Journal of Allergy and Clinical Immunology
language:en
Short-container-title:Journal of Allergy and Clinical Immunology

Author:

Cox Linda,Lieberman Phillip,Wallace Dana,Simons F. Estelle R.,Finegold Ira,Platts-Mills Thomas,Schwartz Lawrence

Funder

National Institute of Allergy and Infectious Diseases

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference6 articles.

1. Second Symposium on the Definition and Management of Anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network Symposium;Sampson;J Allergy Clin Immunol,2006

2. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force report on omalizumab-associated anaphylaxis;Cox;J Allergy Clin Immunol,2007

3. U.S. Food and Drug Administration Approved Risk Evaluation and Mitigation Strategies (REMS) 2011. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm. Accessed February 13, 2011.

4. Delayed allergic reactions to omalizumab: are patients reporting all cases?;Barry;J Allergy Clin Immunol,2008

5. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008;Lin;Ann Allergy Asthma Immunol,2009

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SAFETY OF OMALIZUMAB IN DIFFERENT PATIENT POPULATIONS;Bulletin "Biomedicine and sociology";2024-07-06

2. Implementing Food Oral Immunotherapy Into Clinical Practice: Quality and Safety Perspectives From a US Academic Center;The Journal of Allergy and Clinical Immunology: In Practice;2024-05

3. Anaphylaxis: A 2023 practice parameter update;Annals of Allergy, Asthma & Immunology;2024-02

4. Omalizumab: a quarter of a century in the fight against T2-inflammatory diseases of upper and lower respiratory tract;Meditsinskiy sovet = Medical Council;2023-11-16

5. A risk of serious anaphylatic reactions to asthma biologics: a pharmacovigilance study based on a global real-world database;Scientific Reports;2023-10-17